Adage Capital Partners Gp, L.L.C. Xenon Pharmaceuticals Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $56.4 Billion
- Q2 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 1,290,100 shares of XENE stock, worth $47.3 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
1,290,100
Previous 1,914,749
32.62%
Holding current value
$47.3 Million
Previous $64.2 Million
37.14%
% of portfolio
0.07%
Previous 0.12%
Shares
24 transactions
Others Institutions Holding XENE
# of Institutions
221Shares Held
73.2MCall Options Held
336KPut Options Held
309K-
Avoro Capital Advisors LLC New York, NY5.4MShares$198 Million3.08% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.34MShares$159 Million1.31% of portfolio
-
Braidwell LP Stamford, CT3.61MShares$132 Million6.91% of portfolio
-
Janus Henderson Group PLC London, X03.58MShares$131 Million0.06% of portfolio
-
Capital International Investors Los Angeles, CA3.18MShares$117 Million0.02% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.29B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...